SEQURNA Overview
- Headquarters
- Se
- Website
- www.sequrna.com
- Industry
- Biotechnology Research
- Employees
- 4
- Founded
- 2022
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
About SEQURNA
Introducing next-generation RNase inhibitors - ideal for single-cell and in situ RNA-sequencing SEQURNA's RNase inhibitor makes RNA work and sequencing pipelines more accessible, affordable, and sustainable. Unlike competitors’ recombinant RNase inhibitors, the SEQURNA inhibitor is thermostable and can be shipped and stored at room temperature without affecting performance. These features not only simplify shipping and storage logistics, eliminate batch effects, and reduce costs for the user but also enable new and simplified workflows and novel laboratory protocols, including heat cycles. Propel your biotech business or research, and choose a more environmentally sustainable option for RNase inhibition in your RNA-seq workflows, by becoming an early user of SEQURNA’s RNase inhibitor. Our R&D team is keen to assist and advice in the transition. Find out more at www.sequrna.com or email us at info@sequrna.com
SEQURNA Contact Details
- People in AeroLeads
- 1
SEQURNA Org Chart
Sample employees and titles| Name | Title | Location | Contact |
|---|---|---|---|
| Fredrik Olsson | CEO at Genovis |
View
|
Compare Similar Companies to SEQURNA
Genovis
Biotechnology Research
Alligator Bioscience AB
Biotechnology Research
Epigenica
Biotechnology
Molecular Attraction AB
Biotechnology Research
AAX Biotech AB
Biotechnology Research
Basic Genomics AB
Biotechnology Research
Xpress Genomics
Biotechnology Research
Ciprocity
Biotechnology Research
NEXUS Epigenomics
Biotechnology Research
Moltic Pharma
Research Services